Catalyst Pharmaceuticals (CPRX) Competitors

Summit Therapeutics (NASDAQ:SMMT) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Do insiders and institutionals hold more shares of SMMT or CPRX?

1.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Catalyst Pharmaceuticals shares are owned by institutional investors. 83.7% of Summit Therapeutics shares are owned by company insiders. Comparatively, 14.1% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community believe in SMMT or CPRX?

Catalyst Pharmaceuticals received 185 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 74.88% of users gave Catalyst Pharmaceuticals an outperform vote while only 57.06% of users gave Summit Therapeutics an outperform vote.

Company	Underperform	Outperform
Summit Therapeutics	Outperform Votes 283 57.06%	Underperform Votes 213 42.94%
Catalyst Pharmaceuticals	Outperform Votes 468 74.88%	Underperform Votes 157 25.12%

Which has more risk and volatility, SMMT or CPRX?

Summit Therapeutics has a beta of -1.03, suggesting that its stock price is 203% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.

Does the media refer more to SMMT or CPRX?

In the previous week, Catalyst Pharmaceuticals had 6 more articles in the media than Summit Therapeutics. MarketBeat recorded 9 mentions for Catalyst Pharmaceuticals and 3 mentions for Summit Therapeutics. Catalyst Pharmaceuticals' average media sentiment score of 0.53 beat Summit Therapeutics' score of 0.45 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Catalyst Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer SMMT or CPRX?

Catalyst Pharmaceuticals has a consensus target price of $21.50, suggesting a potential upside of 79.47%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Catalyst Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Is SMMT or CPRX more profitable?

Catalyst Pharmaceuticals has a net margin of 38.76% compared to Summit Therapeutics' net margin of -1,012.41%. Catalyst Pharmaceuticals' return on equity of 34.72% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	-1,012.41%	-70.92%	-26.95%
Catalyst Pharmaceuticals	38.76%	34.72%	28.75%

Which has better valuation & earnings, SMMT or CPRX?

Catalyst Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	$700 thousand	1,873.77	-$78.78 million	-$1.81	-1.04
Catalyst Pharmaceuticals	$214.20 million	5.93	$83.08 million	$0.88	13.61

Summary

Catalyst Pharmaceuticals beats Summit Therapeutics on 16 of the 18 factors compared between the two stocks.